title: [Remnant gastric cancer in which prolonged no change status was maintained with low-dose TS-1--a case report].
abstract: A no change (NC) status could be maintained in a patient with remnant gastric cancer for more than 500 days with low-dose TS-1. The patient was a 68-year-old woman who was found to have remnant gastric cancer during an endoscopic examination in follow-up on an outpatient basis after surgery for hepatocellular carcinoma in our department. Surgery was rejected as a treatment option because of severe liver dysfunction, and the patient was started on oral TS-1 80 mg/day. Both AST and ALT levels increased immediately after the start of TS-1, and TS-1 was discontinued until these levels improved. It was resumed at 50 mg/day, and there were no subsequent adverse reactions. Endoscopic examination on day 69 after the start of TS-1 showed that a partial response (PR) had not been achieved, but the lesion had shrunk. Endoscopy on day 454 after the start of TS-1 showed it had been possible to maintain a similar state. This was a rare case in which it was possible to achieve prolonged same status with low-dose TS-1.
authors.affiliation: Dept. of Gastroenterological Surgery, Osaka City University Graduate School of Medicine.
authors.forename: Masashi
authors.initials: M
authors.lastname: Takemura
authors.forename: Harushi
authors.initials: H
authors.lastname: Osugi
authors.forename: Shigeru
authors.initials: S
authors.lastname: Lee
authors.forename: Shinichi
authors.initials: S
authors.lastname: Taguchi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kaneko
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Kenichirou
authors.initials: K
authors.lastname: Fukuhara
authors.forename: Yuushi
authors.initials: Y
authors.lastname: Fujiwara
authors.forename: Satoshi
authors.initials: S
authors.lastname: Nishizawa
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Kinoshita
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000284:Administration, Oral; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000601:surgery; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000601:surgery; D018365:Neoplasm, Residual; D009378:Neoplasms, Multiple Primary; D010094:Oxonic Acid / Q000008:administration & dosage*; D011725:Pyridines / Q000008:administration & dosage*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid